The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.

Source disclosure

This is a source-linked briefing. Read the original report from Biopharma Dive .